XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Nano Tx Therapeutics [Member]
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Nano Tx Therapeutics [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Nano Tx Therapeutics [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2018 $ 5,225             $ 418,390   $ 1,218 $ (414,383)
Balance (in shares) at Dec. 31, 2018     4,606,000   296,609,000            
Share-based compensation 49             49      
Sale of common stock, net 1,873             1,873      
Sale of common stock, net (in shares)         139,855,000            
Conversion of Convertible Preferred Stock into common stock (share)       (66,000)     1,653,000        
Foreign currency translation adjustment and accumulated other comprehensive income (140)                 (140)  
Net loss (3,150)                   (3,150)
Balance at Mar. 31, 2019 3,857             420,312   1,078 (417,533)
Balance (in shares) at Mar. 31, 2019     4,540,000   438,117,000            
Balance at Dec. 31, 2018 5,225             418,390   1,218 (414,383)
Balance (in shares) at Dec. 31, 2018     4,606,000   296,609,000            
Net loss (12,297)                    
Balance at Jun. 30, 2019 (6,276)             420,404     (426,680)
Balance (in shares) at Jun. 30, 2019     4,540,000   443,117,000            
Balance at Dec. 31, 2018 5,225             418,390   1,218 (414,383)
Balance (in shares) at Dec. 31, 2018     4,606,000   296,609,000            
Balance at Dec. 31, 2019 $ 1,160       $ 4     426,426     (425,270)
Balance (in shares) at Dec. 31, 2019 3,880,588   1,959,000   3,880,588,000            
Balance at Mar. 31, 2019 $ 3,857             420,312   1,078 (417,533)
Balance (in shares) at Mar. 31, 2019     4,540,000   438,117,000            
Share-based compensation 28             28      
Sale of common stock, net 64             64      
Sale of common stock, net (in shares)         5,000,000            
Foreign currency translation adjustment and accumulated other comprehensive income (1,078)                 $ (1,078)  
Net loss (9,147)                   (9,147)
Balance at Jun. 30, 2019 (6,276)             420,404     (426,680)
Balance (in shares) at Jun. 30, 2019     4,540,000   443,117,000            
Balance at Dec. 31, 2019 $ 1,160       $ 4     426,426     (425,270)
Balance (in shares) at Dec. 31, 2019 3,880,588   1,959,000   3,880,588,000            
Share-based compensation $ 12             12      
Net loss (1,087)                   (1,087)
Balance at Mar. 31, 2020 85       $ 4     426,438     (426,357)
Balance (in shares) at Mar. 31, 2020     1,959,000   3,880,588,000            
Balance at Dec. 31, 2019 $ 1,160       $ 4     426,426     (425,270)
Balance (in shares) at Dec. 31, 2019 3,880,588   1,959,000   3,880,588,000            
Sale of common stock, net (in shares) 3,450,000                    
Net loss $ (2,926)                    
Balance at Jun. 30, 2020 $ 3,300       $ 4     431,492     (428,196)
Balance (in shares) at Jun. 30, 2020 4,273,857   1,959,000   4,273,857,000            
Balance at Mar. 31, 2020 $ 85       $ 4     426,438     (426,357)
Balance (in shares) at Mar. 31, 2020     1,959,000   3,880,588,000            
Issuance of common stock for exercise of warrants 366             366      
Issuance of common stock for exercise of warrants (in shares)         162,500,000            
Reclassification of warrant liabilities 4,264             4,264      
Issuance of common stock for in process research and development acquired   $ 381             $ 381    
Issuance of common stock for in process research and development acquired (in share)           230,769,000          
Share-based compensation 43             43      
Net loss (1,839)                   (1,839)
Balance at Jun. 30, 2020 $ 3,300       $ 4     $ 431,492     $ (428,196)
Balance (in shares) at Jun. 30, 2020 4,273,857   1,959,000   4,273,857,000